CGEN Stock Overview
Compugen Ltd., una empresa de descubrimiento y desarrollo terapéutico en fase clínica, investiga, desarrolla y comercializa candidatos terapéuticos y productos en Israel, Estados Unidos y Europa.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Compugen Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.42 |
| 52 Week High | US$3.03 |
| 52 Week Low | US$0.53 |
| Beta | 2.68 |
| 1 Month Change | -17.69% |
| 3 Month Change | 33.70% |
| 1 Year Change | 284.25% |
| 3 Year Change | -70.52% |
| 5 Year Change | -31.05% |
| Change since IPO | -78.25% |
Recent News & Updates
Is Compugen Ltd. (NASDAQ:CGEN) Trading At A 36% Discount?
Apr 05
Compugen Ltd.'s (NASDAQ:CGEN) Price Is Right But Growth Is Lacking After Shares Rocket 26%
Mar 08Recent updates
Is Compugen Ltd. (NASDAQ:CGEN) Trading At A 36% Discount?
Apr 05Compugen Ltd.'s (NASDAQ:CGEN) Price Is Right But Growth Is Lacking After Shares Rocket 26%
Mar 08Compugen (NASDAQ:CGEN) Is In A Good Position To Deliver On Growth Plans
Feb 17Will Compugen (NASDAQ:CGEN) Spend Its Cash Wisely?
Oct 10Is Compugen (NASDAQ:CGEN) In A Good Position To Invest In Growth?
Jun 22Here's Why We're Not Too Worried About Compugen's (NASDAQ:CGEN) Cash Burn Situation
Mar 04Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth
Sep 21Compugen appoints Alberto Sessa as CFO
Sep 12Compugen gets Japanese patent for COM701, anti-PVRIG antibodies
Aug 24Compugen Q2 2022 Earnings Preview
Aug 03Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth
Jun 23Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth
Mar 02Here's Why We're Not Too Worried About Compugen's (NASDAQ:CGEN) Cash Burn Situation
Nov 04Shareholders Will Probably Not Have Any Issues With Compugen Ltd.'s (NASDAQ:CGEN) CEO Compensation
Aug 27Companies Like Compugen (NASDAQ:CGEN) Can Afford To Invest In Growth
Jun 28Compugen gains on takeover speculation after iTeos Therapeutics deal
Jun 14Compugen reports updated COM701 data from Phase 1 study at ASCO21
Jun 08Compugen's COM902 demonstrates potential benefit in cancer
Apr 27Here's Why We're Not At All Concerned With Compugen's (NASDAQ:CGEN) Cash Burn Situation
Mar 15Are Institutions Heavily Invested In Compugen Ltd.'s (NASDAQ:CGEN) Shares?
Feb 08
A Look At The Fair Value Of Compugen Ltd. (NASDAQ:CGEN)
Jan 04Compugen earns $2M milestone under antibody development deal with AstraZeneca
Dec 23Here's Why We're Not At All Concerned With Compugen's (NASDAQ:CGEN) Cash Burn Situation
Nov 30Compugen Ltd. 2020 Q3 - Results - Earnings Call Presentation
Nov 08Compugen: Speculative Play For Immuno-Oncology Exposure
Nov 07Compugen Q3 Earnings Preview
Nov 04Shareholder Returns
| CGEN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -2.0% | -4.3% | -0.8% |
| 1Y | 284.2% | 3.9% | 25.9% |
Rentabilidad frente al sector: CGEN superó al sector US Life Sciences , que obtuvo un rendimiento del -2.8% el año pasado.
Rentabilidad vs. Mercado: CGEN superó al mercado US, que obtuvo un rendimiento del 23.5% el año pasado.
Price Volatility
| CGEN volatility | |
|---|---|
| CGEN Average Weekly Movement | 11.1% |
| Biotechs Industry Average Movement | 12.0% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Precio estable de las acciones: CGENha sido volátil en los últimos 3 meses.
Volatilidad a lo largo del tiempo: CGENha disminuido de 27% a 12% en el último año, pero sigue siendo superior al 75% de los valores de US.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 68 | Anat Cohen-Dayag | https://cgen.com |
Compugen Ltd., una empresa de descubrimiento y desarrollo terapéutico en fase clínica, investiga, desarrolla y comercializa candidatos terapéuticos y productos en Israel, Estados Unidos y Europa. La cartera de productos inmuno-oncológicos de la empresa consta de COM701, un anticuerpo anti-PVRIG que se halla en estudio clínico de fase I para el tratamiento de tumores sólidos; COM902, un anticuerpo terapéutico dirigido contra TIGIT, que se halla en estudio clínico de fase I de monoterapia en pacientes con neoplasias malignas avanzadas mediante escaladas secuenciales de dosis; Bapotulimab, un anticuerpo terapéutico dirigido contra ILDR2 que está en estudio clínico de fase I en pacientes con carcinoma escamoso de cabeza y cuello naïve; y Rilvegostomig, un nuevo anticuerpo biespecífico anti-TIGIT/PD-1, que está en estudio clínico de fase II en pacientes con cáncer de pulmón no microcítico avanzado o metastásico. Su cartera terapéutica también incluye programas de inmuno-oncología en fase inicial centrados en abordar diversos mecanismos de resistencia inmunitaria; y COM503, anticuerpo de alta afinidad, que bloquea la interacción entre la proteína de unión a IL-18 y la IL-18.
Compugen Ltd. Fundamentals Summary
| CGEN fundamental statistics | |
|---|---|
| Market cap | US$216.66m |
| Earnings (TTM) | -US$18.75m |
| Revenue (TTM) | US$33.46m |
6.5x
P/S Ratio-11.6x
P/E RatioIs CGEN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CGEN income statement (TTM) | |
|---|---|
| Revenue | US$33.46m |
| Cost of Revenue | US$2.00m |
| Gross Profit | US$31.46m |
| Other Expenses | US$50.21m |
| Earnings | -US$18.75m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.21 |
| Gross Margin | 94.01% |
| Net Profit Margin | -56.05% |
| Debt/Equity Ratio | 0% |
How did CGEN perform over the long term?
See historical performance and comparison